Posts Tagged ‘blindness’

Blind Patient Reads Words Stimulated Directly Onto The Retina: Neuroprosthetic Device Uses Implant To Project Visual Braille

November 26th, 2012

Grid of electrons directly implanted on the retina.

For the very first time researchers have streamed braille patterns directly into a blind patient’s retina, allowing him to read four-letter words accurately and quickly with an ocular neuroprosthetic device. The device, the Argus II, has been implanted in over 50 patients, many of who can now see color, movement and objects. It uses a small camera mounted on a pair of glasses, a portable processor to translate the signal from the camera into electrical stimulation, and a microchip with electrodes implanted directly on the retina. The study was authored by researchers at Second Sight, the company who developed the device, and has been published in Frontiers in Neuroprosthetics on the 22nd of November.

“In this clinical test with a single blind patient, we bypassed the camera that is the usual input for the implant and directly stimulated the retina. Instead of feeling the braille on the tips of his fingers, the patient could see the patterns we projected and then read individual letters in less than a second with up to 89% accuracy,” explains researcher Thomas Lauritzen, lead author of the paper.

Similar in concept to successful cochlear implants, the visual implant uses a grid of 60 electrodes—attached to the retina—to stimulate patterns directly onto the nerve cells. For this study, the researchers at Second Sight used a computer to stimulate six of these points on the grid to project the braille letters. A series of tests were conducted with single letters as well as words ranging in length from two letters up to four. The patient was shown each letter for half a second and had up to 80% accuracy for short words.

Headset for the Argus II retinal implant device.

“There was no input except the electrode stimulation and the patient recognized the braille letters easily. This proves that the patient has good spatial resolution because he could easily distinguish between signals on different, individual electrodes.” says Lauritzen.

According to Silvestro Micera at EPFL’s Center for Neuroprosthetics and scientific reviewer for the article, “this study is a proof of concept that points to the importance of clinical experiments involving new neuroprosthetic devices to improve the technology and innovate adaptable solutions.”

Primarily for sufferers of the genetic disease Retinitis Pigmentosa (RP), the implant Argus II has been shown to restore limited reading capability of large conventional letters and short words when used with the camera. While reading should improve with future iterations of the Argus II, the current study shows how the Argus II could be adapted to provide an alternative and potentially faster method of text reading with the addition of letter recognition software. This ability to perform image processing in software prior to sending the signal to the implant is a unique advantage of Argus II.

2-sight.eu

Bookmark and Share

Study Suggests Caffeinated Coffee Drinkers at Risk of Developing Vision Loss or Blindness

November 13th, 2012

A new study suggests caffeinated coffee drinkers should limit their intake to reduce their chances of developing vision loss or blindness. According to a scientific paper in Investigative Ophthalmology & Visual Science, heavy caffeinated coffee consumption is associated with an increased risk of developing exfoliation glaucoma, the leading cause of secondary glaucoma worldwide.

The study, The Relation between Caffeine and Coffee Consumption and Exfoliation Glaucoma or Glaucoma Suspect: A Prospective Study in Two Cohorts, is the first to examine the link between caffeinated coffee and exfoliation glaucoma in a U.S. –based population.

“Scandinavian populations have the highest frequencies of exfoliation syndrome and glaucoma,” said author, Jae Hee Kang, ScD, of Channing Division of Network Medicine at Brigham and Women’s Hospital in Boston, Mass. “Because Scandinavian populations also have the highest consumption of caffeinated coffee in the world, and our research group has previously found that greater caffeinated coffee intake was associated with increased risk of primary open-angle glaucoma, we conducted this study to evaluate whether the risk of exfoliation glaucoma or glaucoma suspect may be different by coffee consumption.”

The study was composed of two cohorts: 78,977 women from the Nurses’ Health Study (NHS) and 41,202 men from the Health Professionals Follow-up Study (HPFS) who were at least 40 years of age, did not have glaucoma and reported undergoing eye examinations from 1980 (for NHS participants) and 1986 (for HPFS participants) to 2008. The research team used questionnaires to obtain and validate the consumption of beverages containing caffeine and reviewed medical records to determine incident cases of exfoliation glaucoma, which contributes to elevated pressure sufficient enough to damage the optic nerve, or exfoliation glaucoma suspect that have milder or only suspect optic nerve damage.

A meta-analysis of the two cohorts showed that, compared to abstainers, participants who drank three cups or more of caffeinated coffee daily were at an increased risk of developing exfoliation glaucoma or glaucoma suspect. The researchers did not find associations with consumption of other caffeinated products, such as soda, tea, chocolate or decaffeinated coffee. The results also showed that women with a family history of glaucoma were at an increased risk.

Kang, along with his colleagues, report that this study represents a much needed effort to better understand the causes of exfoliation glaucoma, which are largely unknown.

“Because this is the first study to evaluate the association between caffeinated coffee and exfoliation glaucoma in a U.S. population, confirmation of these results in other populations would be needed to lend more credence to the possibility that caffeinated coffee might be a modifiable risk factor for glaucoma,” said Kang. “It may also lead to research into other dietary or lifestyle factors as risk factors.”

 

The ARVO peer-reviewed journal Investigative Ophthalmology & Visual Science (IOVS) publishes results from original hypothesis-based clinical and laboratory research studies, as well as Reviews, Perspectives, and Special Issues. IOVS 2009 Impact Factor ranks No. 4 out of 45 among ophthalmology journals. The journal is online-only and articles are published daily.

The Association for Research in Vision and Ophthalmology (ARVO) is the largest eye and vision research organization in the world. Members include nearly 13,000 eye and vision researchers from over 80 countries. ARVO encourages and assists research, training, publication and knowledge-sharing in vision and ophthalmology.

www.arvo.org

Bookmark and Share

Massachusetts Eye and Ear Researchers Discover Elusive Gene That Causes a Form of Blindness From Birth

August 15th, 2012

Researchers from the Massachusetts Eye and Ear Infirmary, The Children’s Hospital of Philadelphia, Loyola University Chicago Health Sciences Division and their collaborators have isolated an elusive human gene that causes a common form of Leber congenital amaurosis (LCA), a relatively rare but devastating form of early-onset blindness. The new LCA gene is called NMNAT1. Finding the specific gene mutated in patients with LCA is the first step towards developing sight-saving gene therapy.

LCA is an inherited retinal degenerative disease characterized by reduced vision in infancy. Within the first few months of life, parents usually notice a lack of visual responsiveness and unusual roving eye movements known as nystagmus. LCA typically involves only vision problems, but can be accompanied by disease in other organ systems in a minority of patients. LCA is a common reason children are enrolled in schools for the blind.

“The immediate benefit of this discovery is that affected patients with mutations in this new LCA gene now know the cause of their condition,” said Eric Pierce, M.D., Ph.D., co-senior author and director of the Ocular Genomics Institute at Mass. Eye and Ear. “Scientists now have another piece to the puzzle as to why some children are born with LCA and decreased vision. The long-term goal of our research is to develop therapies to limit or prevent vision loss from these disorders.”

Eric Pierce, M.D., Ph.D.

NMNAT1 is the 18th identified LCA gene. The gene resides in a region that was known to harbor an LCA gene since 2003, but the specific disease gene has been undiscovered until now. These findings will be published on July 29 in the online edition of Nature Genetics.

To identify NMNAT1, scientists performed whole exome sequencing of the family of two siblings who initially presented for evaluation of LCA but who had no mutations in any of the known LCA genes. Being seen by a multi-disciplinary team that took the case from careful clinical characterization to genetic testing to the research laboratory was an essential ingredient for success.

“By using whole exome sequencing, we found a mutation in a gene that no one could have predicted would be associated with LCA,” said Dr. Pierce.

“Whereas most of the known LCA genes involve dysfunction of retinal ciliary proteins necessary for light detection in the eye, NMNAT1 is uniquely distinguished by being the first metabolic enzyme linked to LCA,” said Marni J. Falk, M.D., co-first author and Clinical Geneticist at The Children’s Hospital of Philadelphia and University of Pennsylvania Perelman School of Medicine.

Marni Falk, M.D.

Having found a mutation in NMNAT1 in this one family, the investigators next asked if mutations in NMNAT1 also cause disease in other patients with LCA. Screening of 284 unrelated patients with LCA from the United States, England, France and India allowed them to identify 13 other patients with mutations in NMNAT1 as the cause of their disease.

Drs. Falk, Pierce and colleagues also studied how the identified mutations in NMNAT1 affect the function of the NMNAT1 protein, and thus may cause dysfunction and death of the light sensitive photoreceptor cells in the retina. Working together with Eiko Nakamaru-Ogiso, Ph.D., in the Department of Biochemistry and Biophysics at The University of Pennsylvania, they found that mutations in NMNAT1 appear to decrease the ability of the NMNAT1 protein to produce NAD+, a key mediator of cellular signaling and energetics.

Early treatment for patients with NMNAT1-related LCA could be especially beneficial.

Researchers found that all but the youngest patient with NMNAT1 mutations had damage to the macula, the center of the retina that is needed for central vision. “This 4-year-old girl who doesn’t have central vision loss yet can possibly benefit substantially if we can devise a therapy for her NMNAT1-mediated LCA that prevents her from developing severe central vision loss,” Dr. Pierce said.

This study is an example of the multidisciplinary collaboration among the three institutions, using exome sequencing to discover genes involved in inherited diseases caused by mutations of a single gene. “With the robust database and pipeline that we have developed, we have analyzed more than 300 whole exomes of patients and families with single-gene diseases,” said Dr. Xiaowu Gai, co-senior author and director of the Center for Biomedical Informatics at Loyola University Chicago Stritch School of Medicine. “We are following up on a number of strong candidate genes. We are sequencing many new samples and expect similar exciting discoveries for other diseases.”

 

About Massachusetts Eye and Ear
Massachusetts Eye and Ear clinicians and scientists are driven by a mission to find cures for blindness, deafness and diseases of the head and neck. After uniting with Schepens Eye Research Institute in 2011, Massachusetts Eye and Ear in Boston became the world’s largest vision and hearing research center, offering hope and healing to patients everywhere through discovery and innovation. Massachusetts Eye and Ear is a Harvard Medical School teaching hospital and trains future medical leaders in ophthalmology and otolaryngology, through residency as well as clinical and research fellowships. Internationally acclaimed since its founding in 1824, Massachusetts Eye and Ear employs full-time, board-certified physicians who offer high-quality and affordable specialty care that ranges from the routine to the very complex. U.S. News & World Report’s “Best Hospitals Survey” has consistently ranked the Massachusetts Eye and Ear Departments of Otolaryngology and Ophthalmology as top five in the nation. Massachusetts Eye and Ear is home to the Ocular Genomics Institute which aims to translate the promise of personalized genomic medicine into clinical care for ophthalmic disorders.

www.masseyeandear.org

Bookmark and Share

Debilitating Eyesight Problems Are On The Decline For Older Americans

July 30th, 2012

Today’s senior citizens are reporting fewer visual impairment problems than their counterparts from a generation ago, according to a new Northwestern Medicine study. Improved techniques for cataract surgery and a reduction in the prevalence of macular degeneration may be the driving forces behind this change, the researchers said.

“From 1984 until 2010, the decrease in visual impairment in those 65 and older was highly statistically significant,” said Angelo P. Tanna, M.D., first author of the study. “There was little change in visual impairments in adults under the age of 65.”

The study, published in the journal Ophthalmology, shows that in 1984, 23 percent of elderly adults had difficulty reading or seeing newspaper print because of poor eyesight. By 2010, there was an age-adjusted 58 percent decrease in this kind of visual impairment, with only 9.7 percent of elderly reporting the problem.

Angelo P. Tanna, M.D.

There was also a substantial decline in eyesight problems that limited elderly Americans from taking part in daily activities, such as bathing, dressing or getting around inside or outside of the home, according to the study.

“The findings are exciting, because they suggest that currently used diagnostic and screening tools and therapeutic interventions for various ophthalmic diseases are helping to prolong the vision of elderly Americans,” Tanna said.

Tanna is the vice chairman of ophthalmology at Northwestern University Feinberg School of Medicine and an attending physician at Northwestern Memorial Hospital. Stephen Kaye, of the Institute for Health & Aging and Disability Statistics Center, University of California, is the second author of the study.

The study used self-reported data collected from 1984 to 2010 through two major population-based surveys, the National Health Interview Survey and the Survey of Income and Program Participation.

Survey questions revealed how vision problems can impact the daily activities and quality of life of Americans and helped researchers analyze trends in the prevalence of visual impairment of adults in the United States.

While this study didn’t identify any of the causes of the change in the prevalence of visual impairment, Tanna said there are three likely reasons for the decline:

  • Improved techniques and outcomes for cataract surgery
  • Less smoking, resulting in a drop in the prevalence of macular degeneration
  • Treatments for diabetic eye diseases are more readily available and improved, despite the fact that the prevalence of diabetes has increased

Future studies should identify which treatment strategies help prevent vision loss in older adults and then make those treatments available to as many people as possible, Tanna said.

This study was funded by a grant from Research to Prevent Blindness and by the National Institute on Disability and Rehabilitation Research, US Department of Education (grant H133B080002).

feinberg.northwestern.edu

Bookmark and Share

Childhood Obesity Increases Likelihood of a Cranial Disorder That May Cause Blindness

June 8th, 2012

Example of an optic nerve with mild papilledema

Children who are overweight or obese – particularly older, non-Hispanic white girls – are more likely to have a neurological disorder known as idiopathic intracranial hypertension, a rare condition that can result in blindness, according to a new study.

In a cross-sectional, population-based study of 900,000 children ages 2-19 years old, researchers found 78 cases of pediatric idiopathic intracranial hypertension.

The condition occurred most frequently in overweight or obese, non-Hispanic white teenage girls—85 percent of the children with IIH were girls 11-19, nearly half were non-Hispanic white, and 73 percent were overweight or obese.

Importantly, the study also found a strong association between IIH and increasing weight class: extremely obese adolescents were 16 times more likely than normal weight children to have IIH; moderately obese children, 6 times more likely; and overweight children, 3.5 times more likely.

“Childhood obesity has again been shown to be associated with a serious disease,” said study lead author Sonu M. Brara, MD, of the Kaiser Permanente Los Angeles Medical Center Neurology Department.

“This research is the strongest evidence to date that obesity is associated with IIH in children—it also suggests that the childhood obesity epidemic is likely to lead to increased morbidity from IIH, including blindness,” he stated.

This study adds to the growing evidence base about data on the prevalence of obesity and prevention of it among children. Earlier this month the Institute of Medicine released its Accelerating Progress in Obesity Prevention offering recommendations, strategies, and action steps for stakeholders and sectors to accelerate progress in preventing obesity.

In adults, IIH is a relatively rare disorder that predominately affects overweight or obese women ages 20 to 44 with an incidence rate of 15 per 100,000 individuals. The disorder is characterized by increased pressure around the brain in the absence of other diseases, with symptoms including headache, blurred vision, nausea, and eye movement abnormalities. The ailment can lead to blindness in up to 10 percent of patients, particularly when not recognized and treated promptly.

The children and adolescents in the study were enrolled in the Kaiser Permanente Southern California integrated health plan from 2007 to 2009. The study included measured height and weight and diagnosis of IIH.

“Our findings may help improve the early diagnosis and treatment of IIH in young patients,” said Dr. Brara.

“Overweight and obese children appear to have more IIH symptoms at onset than normal weight children. We suggest that clinicians carefully screen adolescents who are overweight or obese and present with symptoms of IIH, such as headache, blurred vision, and eye movement abnormalities,” he added.

The study was published in The Journal of Pediatrics.


Bookmark and Share

Stem Cells Can Repair A Damaged Cornea

April 24th, 2012

A new cornea may be the only way to prevent a patient going blind – but there is a shortage of donated corneas and the queue for transplantation is long. Scientists at the Sahlgrenska Academy have for the first time successfully cultivated stem cells on human corneas, which may in the long term remove the need for donators.

Approximately 500 corneal transplantations are carried out each year in Sweden, and about 100,000 in the world. The damaged and cloudy cornea that is turning the patient blind is replaced with a healthy, transparent one. But the procedure requires a donated cornea, and there is a severe shortage of donated material. This is particularly the case throughout the world, where religious or political views often hinder the use of donated material.

Replacing donated corneas
Scientists at the Sahlgrenska Academy, University of Gothenburg, have taken the first step towards replacing donated corneas with corneas cultivated from stem cells.

Scientists Charles Hanson and Ulf Stenevi have used defective corneas obtained from the ophthalmology clinic at Sahlgrenska University Hospital in Mölndal. Their study is now published in the journal Acta Ophthalmologica, and shows how human stem cells can be caused to develop into what are known as “epithelial cells” after 16 days’ culture in the laboratory and a further 6 days’ culture on a cornea. It is the epithelial cells that maintain the transparency of the cornea.

Scientist Charles Hanson

First time ever on human corneas
“Similar experiments have been carried out on animals, but this is the first time that stem cells have been grown on damaged human corneas. It means that we have taken the first step towards being able to use stem cells to treat damaged corneas”, says Charles Hanson.

“If we can establish a routine method for this, the availability of material for patients who need a new cornea will be essentially unlimited. Both the surgical procedures and the aftercare will also become much more simple”, says Ulf Stenevi.

Few clinics conduct tranplants
Only a few clinics are currently able to transplant corneas. Many of the transplantations in Sweden are carried out at the ophthalmology clinic at Sahlgrenska University Hospital, Department of Ophthalmology, Mölndal.

The article “Transplantation of human embryonic stem cells onto a partially wounded human cornea in vitro” was published in Acta Ophthalmologica on 27 January.

www.sahlgrenska.gu.se

Bookmark and Share

University of Florida Researchers Develop Gene Therapy That Could Correct Blindness

March 6th, 2012

A new gene therapy method developed by University of Florida researchers has the potential to treat a common form of blindness that strikes both youngsters and adults. The technique works by replacing a malfunctioning gene in the eye with a normal working copy that supplies a protein necessary for light-sensitive cells in the eye to function. The findings are published in the Proceedings of the National Academy of Sciences online.

Several complex and costly steps remain before the gene therapy technique can be used in humans, but once at that stage, it has great potential to change lives.

“Imagine that you can’t see or can just barely see, and that could be changed to function at some levels so that you could read, navigate, maybe even drive — it would change your life considerably,” said study co-author William W. Hauswirth, Ph.D., the Rybaczki-Bullard professor of ophthalmology in the UF College of Medicine and a professor and eminent scholar in department of molecular genetics and microbiology and the UF Genetics Institute. “Providing the gene that’s missing is one of the ultimate ways of treating disease and restoring significant visual function.”

William W. Hauswirth, Ph.D. and Alfred S. Lewin, Ph.D.

The researchers tackled a condition called X-linked retinitis pigmentosa, a genetic defect that is passed from mothers to sons. Girls carry the trait, but do not have the kind of vision loss seen among boys. About 100,000 people in the U.S. have a form of retinitis pigmentosa, which is characterized by initial loss of peripheral vision and night vision, which eventually progresses to tunnel vision, then blindness. In some cases, loss of sight coincides with the appearance of dark-colored areas on the usually orange-colored retina.

The UF researchers previously had success pioneering the use of gene therapy in clinical trials to reverse a form of blindness known as Leber’s congenital amaurosis. About 5 percent of people who have retinitis pigmentosa have this form, which affects the eye’s inner lining.

“That was a great advance, which showed that gene therapy is safe and lasts for years in humans, but this new study has the potential for a bigger impact, because it is treating a form of the disease that affects many more people,” said John G. Flannery, Ph.D., a professor of neurobiology at the University of California, Berkeley who is an expert in the design of viruses for delivering replacement genes. Flannery was not involved in the current study.

The X-linked form of retinitis pigmentosa addressed in the new study is the most common, and is caused by degeneration of light-sensitive cells in the eyes known as photoreceptor cells. It starts early in life, so though affected children are often born seeing, they gradually lose their vision.

“These children often go blind in the second decade of life, which is a very crucial period,” said co-author Alfred S. Lewin, Ph.D., a professor in the UF College of Medicine department of molecular genetics and microbiology and a member of the UF Genetics Institute. “This is a compelling reason to try to develop a therapy, because this disease hinders people’s ability to fully experience their world.”

Both Lewin and Hauswirth are members of UF’s Powell Gene Therapy Center.

The UF researchers and colleagues at the University of Pennsylvania performed the technically challenging task of cloning a working copy of the affected gene into a virus that served as a delivery vehicle to transport it to the appropriate part of the eye. They also cloned a genetic “switch” that would turn on the gene once it was in place, so it could start producing a protein needed for the damaged eye cells to function.

After laboratory tests proved successful, the researchers expanded their NIH-funded studies and were able to cure animals in which X-linked retinitis pigmentosa occurs naturally. The injected genes made their way only to the spot where they were needed, and not to any other places in the body. The study gave a good approximation of how the gene therapy might work in humans.

“The results are encouraging and the rescue of the damaged photoreceptor cells is quite convincing,” said Flannery, who is on the scientific advisory board of the Foundation Fighting Blindness, which provided some funding for the study. “Since this type of study is often the step before applying a treatment to human patients, showing that it works is critical.”

The researchers plan to repeat their studies on a larger scale over a longer term, and make a version of the virus that proves to be safe in humans. Once that is achieved, a pharmaceutical grade of the virus would have to be produced and tested before moving into clinical trials in humans. The researchers will be able to use much of the technology they have already developed and used successfully to restore vision.

University of Florida

Bookmark and Share

Report Shows Risk of Blindness Halved Over Last Decade

February 21st, 2012

Age-related macular degeneration (AMD) is the most frequent cause of blindness in the Western World. A report from the University of Copenhagen and Glostrup Hospital in Denmark shows the number of new cases of blindness and severe visual loss in Denmark has been halved during the last ten years.

The study published in American Journal of Ophthalmology examined the records of 11,848 new cases of legal blindness. The rate of blindness from AMD fell from 522 cases per million inhabitants aged 50 years or older in 2000, to 257 cases per million in 2010, a reduction by over 50 per cent.

The bulk of the decrease occurred after 2006, following the introduction of new effective treatment for wet AMD, which is characterized by leaking blood vessels having formed under the fovea. The treatment consists of repeated injections into the eye of a medication that inhibits the signalling molecule vascular endothelial growth factor (VEGF).

Similar findings in Israel
The observations from Denmark were published together with a corroborating report from Israel that found comparable changes in the incidence of legal blindness in that country. Read the report “Time Trends in the Incidence and Causes of Blindness in Israel”.

Current treatment of wet AMD, also called neovascular AMD, consists of repeated injections into the vitreous, an inner compartment of the eye, of a medication designed to inhibit the action of VEGF. VEGF is a distress signal released from ailing cells of the aging retina. VEGF can cause formation of brittle blood vessels that leak blood and cause scar formation under the fovea. The fovea is central area of the retina where reading vision is located. Wet AMD is a very frequent cause of loss of reading vision.

Michael Larsen

Results show impact on public health
One of the authors behind the Danish study, Michael Larsen, Professor of Clinical Ophthalmology at the University of Copenhagen, is excited about the results.

“The massive implementation of modern wet AMD therapy has been a challenge. It is therefore very important that we can now show an impact on public health and it is wonderful to see a reduction in severe visual loss. The study did not examine moderate visual loss, but there are undoubtedly also a lot of people who avoided loosing their drivers license and their reading vision,” says Michael Larsen.

A turning point in eye care
The data for the study is provided by Danish Association of the Blind, which membership enrollment during the period of 2000-2010 was charted and categorized by diagnoses.

“The reduction in new cases of blindness is a turning point for eyecare in Denmark. We look forward to seeing further progress in eye research, especially in the hereditary eye diseases that cause blindness in children and young adults,” says Thorkild Olesen, Chairman of the Danish Association of the Blind.

www.ku.dk

Bookmark and Share

Chlamydia Trachomatis Bacteria Used as a Vaccine To Prevent Trachoma, The World’s Leading Cause of Infectious Blindness

November 25th, 2011

An attenuated, or weakened, strain of Chlamydia trachomatis bacteria can be used as a vaccine to prevent or reduce the severity of trachoma, the world’s leading cause of infectious blindness, suggest findings from a National Institutes of Health study in monkeys.

Anthony S. Fauci, M.D.

“This work is an important milestone in the development of a trachoma vaccine,” noted Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID) at NIH. “If this approach demonstrates continued success, the implications could be enormous for the tens of millions of people affected by trachoma, a neglected disease of poverty primarily seen in Asia and sub-Saharan Africa.”

In their study, published in the Journal of Experimental Medicine online, scientists from NIAID, led by Harlan Caldwell, Ph.D., describe how they tested their vaccine concept in a series of experiments. First they infected six cynomolgus macaques with the strain of C. trachomatis that they had weakened by removing a small piece of DNA. The scientists observed that the monkeys spontaneously cleared the infection within 14 days with no or minimal signs of ocular disease. The animals then were exposed twice more to the weakened strain at four- and eight-week intervals, but the animals still showed no signs of trachoma despite being infected.

Harlan Caldwell, Ph.D.

According to Dr. Caldwell, this finding is particularly significant because repeated C. trachomatis infections typically lead to more severe eye disease in people. The infected animals did not develop eye disease, and they all mounted robust immune responses.

The same six macaques then were exposed to a highly virulent strain of C. trachomatis as were six other macaques in a control group that had not been vaccinated. Three of the macaques in the vaccine group showed no signs of infection or disease, and the three others showed greatly reduced infection compared with monkeys in the control group. All six macaques in the control group became infected and displayed moderate to severe eye disease that persisted for between two and four months.

Macaques are used in trachoma studies because their immune responses closely predict those of humans. The animals in the study were treated with antibiotics after completion of the experiments, and all recovered completely.

The NIAID researchers are currently exploring how they can move their vaccine into human clinical trials.

Tracomatous Scarring: The presence of scarring in the tarsal conjunctiva. Scars are easily visible as white lines, bands, or sheets in the tarsal conjunctiva.

If left untreated, prolonged trachoma infection can cause a person’s eyelids to fold inward, so that the eyelashes rub the eyeball and scar the cornea. This can result in impaired vision and sometimes blindness. Trachoma is treatable with antibiotics, although in many parts of the world people have limited access to treatment. Currently, there is no vaccine for trachoma. Trachoma experts estimate that approximately 1.3 million people are blind from trachoma, 1.8 million people have low vision as a result of the disease, and an estimated 40 million people have active trachoma. Trachoma is most often spread through direct personal contact, shared towels and other cloths, and flies that have come in contact with the eyes or nose of an infected person.

Chlamydia diseases include sexually transmitted infections, which can result in pelvic inflammatory disease that can cause infertility in women, as well as trachoma. According to the NIAID researchers, findings from this study also could lead to the development of a vaccine against sexually transmitted Chlamydia infections. The Centers for Disease Control and Prevention received more than 1.2 million reports of Chlamydia infections in 2009.


Bookmark and Share

Canadians Not Doing Enough To Protect Themselves From The “Silent Thief of Sight”

November 15th, 2011

Dr. Cindy Hutnik

Glaucoma is the second leading cause of blindness worldwide. Although it can be treated, new research shows Canadians may not be doing enough to protect themselves. According to a new study by Lawson Health Research Institute’s Dr. Cindy Hutnik, many Canadian glaucoma patients are not screened until the disease has reached moderate or advanced stages.

Glaucoma is known as the “silent thief of sight.” It slowly and irreversibly destroys the optic nerve – so slowly, in fact, that many people don’t realize they have glaucoma until it reaches advanced stages. To maintain eye health, preventive screening is vital. Yet despite a spectrum of known risk factors, it appears many Canadians are not checking for them.

In a multi-centre study, Hutnik and her colleagues examined the risk factors shared by 404 newly diagnosed patients across 18 Canadian locations. Each was assessed for demographic information, medical history, and ocular family history, as well as a complete eye exam. Results were largely consistent with the international standards, confirming older age, structural abnormalities and deterioration, and high intraocular pressure as leading glaucoma risk factors. In a surprising twist, however, 48% of these new diagnoses – nearly half – were already at moderate to advanced stages.

It is not clear why Canadians are not screening for glaucoma earlier. Researchers suspect the slow disease progression may not project the same urgency as, for example, a broken limb. The additional cost of screening, which is not covered by OHIP, may also be a deterrent. Researchers have even suggested that available screening measures may not be sensitive enough to detect the complex spectrum of risk factors at early stages. While investigation continues, Dr. Hutnik urges Canadians to keep a close eye on the situation.

“Almost half to two-thirds of your optic nerve is dead before you even get a visual field defect,” she explains. “If you’re late getting your clinical screening test, the nerve has been dying for a long time and once it’s dead, it’s dead. You can only prevent it from getting worse.”

Dr. Hutnik is an Associate Scientist at Lawson’s Centre for Clinical Investigation and Therapeutics, and a Physician at the Ivey Eye Institute at St. Joseph’s Health Care London. She is also a Professor in the Departments of Ophthalmology and Pathology at The University of Western Ontario, and an Adjunct Professor in the Department of Chemistry & Biochemistry and the University of Windsor.

www.lawsonresearch.com

Bookmark and Share